Valuation: Lundbeck

Market Cap 40.88B 6.23B 5.47B 5.06B 4.66B 8.81B 597B 8.98B 60.36B 23.67B 293B 23.41B 22.9B 1,012B P/E 2026 *
9.3x
P/E 2027 * 9.26x
Enterprise Value 44.97B 6.86B 6.01B 5.57B 5.13B 9.69B 656B 9.88B 66.39B 26.04B 322B 25.75B 25.19B 1,113B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 1.58x
Free-Float
30.76%
Yield 2026 *
3.53%
Yield 2027 * 3.62%
1 day+0.14%
1 week-1.09%
Current month-0.68%
1 month-0.55%
3 months+6.75%
6 months-5.95%
Current year+0.41%
1 week 35.9
Extreme 35.9
37.45
1 month 35.65
Extreme 35.65
37.75
Current year 31.4
Extreme 31.4
39.9
1 year 28.5
Extreme 28.5
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%-1.09% - - 6.25B
+0.60%+3.14%+13.04%+97.44% 94.36B
-0.68%-1.58%+44.58%+150.24% 55.23B
+3.55%+4.66%+2.10%+269.62% 22.56B
+1.24%+1.30%-14.05%-22.35% 8.01B
-0.75%-2.96%-27.34%-35.23% 7.6B
+0.72%+0.66%-10.56%-27.84% 6.66B
+0.81%+1.69%-1.69%+23.87% 5.36B
+1.00%+2.43%-5.24%-6.08% 3.68B
+0.95%+0.59%+12.25%+16.43% 3.34B
Average +0.77%+0.59%+1.45%+51.79% 22.98B
Weighted average by Cap. +0.57%+0.98%+16.26%+111.71%

Financials

2026 *2027 *
Net sales 25.79B 3.93B 3.45B 3.19B 2.94B 5.56B 376B 5.67B 38.08B 14.93B 185B 14.77B 14.45B 638B 25.87B 3.94B 3.46B 3.2B 2.95B 5.58B 378B 5.69B 38.19B 14.98B 185B 14.81B 14.49B 640B
Net income 4.55B 694M 609M 564M 519M 982M 66.45B 1B 6.72B 2.64B 32.63B 2.61B 2.55B 113B 4.6B 701M 615M 569M 524M 991M 67.09B 1.01B 6.79B 2.66B 32.95B 2.63B 2.57B 114B
Net Debt 4.09B 623M 547M 506M 466M 881M 59.67B 899M 6.04B 2.37B 29.3B 2.34B 2.29B 101B -44.13M -6.73M -5.9M -5.47M -5.03M -9.52M -644M -9.7M -65.16M -25.56M -316M -25.27M -24.72M -1.09B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
13/07/26 DKK 36.35 +0.14% 67,337
10/07/26 DKK 36.30 0.00% 70,570
09/07/26 DKK 36.30 -1.09% 88,750
08/07/26 DKK 36.70 -0.14% 55,384
07/07/26 DKK 36.75 0.00% 99,517
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
42.48DKK
Average target price
47.62DKK
Spread / Average Target
+12.11%

Quarterly revenue - Rate of surprise